Physicians' Academy for Cardiovascular Education

Covid-19

Overview of recent news and publications on COVID-19 and cardiovascular disease

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 13, 2022 - Prof. Richard Hobbs, MD

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD

Advantages of the digital 2020 ESC Congress

3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD

Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated

3' education - Aug. 30, 2020 - Prof. Barbara Casadei, MD

Cardiac abnormalities in recovered COVID-19 patients

3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD

Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy

3' education - May 8, 2020 - Enrico Baldi, MD

Venous thromboembolism in COVID-19 patients

5' education - May 6, 2020 - Prof. Saskia Middeldorp

Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms

5' education - May 1, 2020 - Prof. Naveed Sattar, MD

COVID-19 associated thrombotic complications

5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
Lecture 1 out of 3

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
Lecture 2 out of 3

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
Lecture (panel discussion) 3 out of 3

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein

CAPACITY COVID: a registry of CV variables in patients with COVID-19

3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD

Need to restart and catch up in CVD prevention in time of COVID-19

10' education - June 13, 2022 - Prof. Richard Hobbs, MD

"During the pandemic, we have lost sight of long-term conditions that are the biggest contributors to worse outcomes", says prof. Hobbs. "We need to restart and catch up in CVD prevention ASAP."

2022 ACC expert consensus pathway on cardiovascular consequences of COVID-19

News - Mar. 24, 2022

The expert consensus pathway provides recommendations for the evaluation and management of adults with myocarditis and long COVID following COVID-19 infection.

Increased risk of incident CV outcomes in the post-acute phase of COVID-19

Literature - Feb. 15, 2022 - Xie Y et al. - Nat Med. 2022

A study shows that individuals in the post-acute phase of COVID-19 exhibited increased risks and 12-month burdens of incident CV diseases, compared to individuals with no evidence of SARA-CoV-2 infection.

Subclinical multi-organ affection after recovery from mild to moderate COVID-19

Literature - Jan. 20, 2022 - Petersen EL, et al. - Eur Heart J 2021
A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

A cross-sectional study showed subclinical signs of affection of the pulmonary, cardiac, coagulation and renal systems in mainly non-hospitalized individuals who had mild to moderate SARS-CoV-2 infection ~9 months ago.

Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk

3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD
Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a  high thrombotic risk, according to prof. Verheugt.

Anticoagulation after discharge may be necessary for a short time in patients who were hospitalized due to COVID-19 and have a high thrombotic risk, according to prof. Verheugt.

Extended thromboprophylaxis with NOAC after hospitalization for COVID-19 improves outcomes

Literature - Jan. 11, 2022 - Ramacciotti E, et al. - Lancet 2022

The MICHELLE trial shows that extended post-discharge thromboprophylaxis with the NOAC rivaroxaban for 35 days improved clinical outcomes compared to no anticoagulation in patients with high risk of thromboembolism who were hospitalized due to COVID-19.

Guidance document on diagnosis and management of CVD during the COVID-19 pandemic

News - Dec. 6, 2021

The Task Force for the management of COVID-19 of the ESC has published two documents that are aimed to provide guidance for the diagnosis and management of CVD during the COVID-19 pandemic.

No change in organ support-free days with P2Y12i in non-critically ill COVID-19 patients

News - Nov. 17, 2021

AHA 2021 As part of the ACTIV-4a study, it was examined whether use of P2Y12 inhibitors (ticagrelor or clopidogrel) changed the number of organ support-free days in a period of 28 days in non-critically ill hospitalized patients with COVID-19.

No significant improvement of outcomes with EPA in COVID-19

3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19. patiënten met COVID-19.

AHA 2021 Rafael Diaz explains the rationale and shares the results of the PREPARE-IT-2-study, which investigated whether icosapent ethyl resulted in a reduction of clinical outcomes in patients with COVID-19.

Highly-purified EPA does not reduce clinical outcomes in non-hospitalized COVID-19 patients

News - Nov. 15, 2021

AHA 2021 The PREPARE IT-2 trial enrolled non-hospitalized COVID-19 patients and showed that icosapent ethyl did not reduce COVID-19-related hospitalization or death compared to placebo after 28 days.

Therapeutic dose of heparin in COVID-19 - the jury is still out

5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD
Is a therapeutic dose of heparin in COVID-19 patients more effective than the standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

Is a therapeutic dose of heparin in COVID-19 patients more effective than standard dose heparin? Prof. ten Cate gives an update on the most recent findings.

Therapeutic-dose of heparin does not improve outcomes in critically ill COVID-19 patients

Literature - Aug. 16, 2021 - The REMAP-CAP, ACTIV-4a, and ATTACC Investigators, et al. - NEJM 2021
In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

In an open-label, multiplatform, randomized trial, therapeutic-dose anticoagulation with unfractionated or low-molecular-weight heparin did not improve clinical outcomes compared to usual-care pharmacologic thromboprophylaxis in critically ill COVID-19 patients.

Covid-19